Sharemaestro company-news research for GSK plc (GS71), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
GER
Germany
Insufficient evidence
Company news sentiment
Latest GS71 news and sentiment
GSK plc
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
No current company-news score
No company-specific headline in the last 30 days currently passes the date and relevance checks. The dash means no score; it is not a neutral observation.
Available information
-3.0% over one week, -2.9% over four weeks, trend inactive, and near fair-value range.
Why there is no score
No recent company story is strong enough to produce a score.
Confidence is 0/100, below the threshold for a firm score.
—/100
News scoreNo qualifying directional evidence
0/100
Confidencethin evidence
0%/100
Company news0 company stories
N/A/100
Story agreementrequires at least 2 stories
News history
Daily score and story count over 30 days
No 30-day history yet
The chart will begin when a dated company headline passes the relevance and freshness checks.
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence0
0 after freshness weightingSource breadth0
0 independent publishersCompany relevance0
share tied directly to this companyFreshness0
recency-weighted evidenceAgreement0
requires at least 2 storiesPublisher mix0
less reliance on one publisherPrice and news history
Weekly price and news-score history
No sufficiently fresh, directly relevant company news is available for a price comparison.
26 completed price weeks15 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
10 Apr07 Jul02 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
02 Oct 202651EUR 20.870001-3.0%
25 Sep 202652EUR 21.52-1.3%
18 Sep 202653EUR 21.809999+5.7%
11 Sep 202652EUR 20.639999-4.0%
04 Sep 202654EUR 21.5-0.6%
28 Aug 202650EUR 21.629999-3.6%
21 Aug 202651EUR 22.43+5.7%
14 Aug 202651EUR 21.23-6.4%
Insufficient evidence
News subjects
What is shaping the score
News subjects will appear when current company stories are available.
Source mix
Where the evidence comes from
No current publisher evidence is available.
Recurring subjects
Subjects appearing most often
Topic structure will appear when classified tags are present in the current feed.
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
26 Jun50 neutral04 Oct 15:52
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 04 Oct 15:52 | 51 | +0 | 17/100 (-3) | 39 (-9) | Provisional |
| 01 Oct 23:59 | 51 | +0 | 20/100 (-2) | 48 (-2) | Provisional |
| 30 Sep 23:59 | 51 | +0 | 22/100 (+3) | 50 (+2) | Provisional |
| 29 Sep 23:59 | 51 | -1 | 19/100 (-1) | 48 (+2) | Provisional |
| 28 Sep 23:59 | 52 | -1 | 20/100 (-7) | 46 (+1) | Provisional |
| 24 Sep 23:59 | 53 | +1 | 27/100 (+5) | 45 (+4) | Provisional |
| 23 Sep 23:59 | 52 | -1 | 22/100 (-2) | 41 (+1) | Provisional |
| 21 Sep 23:59 | 53 | -1 | 24/100 (-6) | 40 (+1) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 0 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
No directional evidence to attribute yet
Company news can still be read below. Influence bars appear when a current story qualifies for the directional score.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
No current company news qualifies
No company-specific headline in the last 30 days currently meets the relevance and date checks. Older readings remain in the history below.
Earlier company news
GS71 news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
13Aug 2026
ArchivedNeutral tone
Could GSK plc (GSK)’s Pipeline Acceleration Unlock a New Growth Era?
On July 28, GSK plc (NYSE:GSK) reported its second-quarter financial results, delivering strong core operational performance and showcasing steady commercial momentum. The firm's total Q2 turnover reached £8.4 billion, marking a 5% increase year-over-year at constant exchange rates (CER),…
Article detailsHistorical record
On July 28, GSK plc (NYSE:GSK) reported its second-quarter financial results, delivering strong core operational performance and showcasing steady commercial momentum. The firm's total Q2 turnover reached £8.4 billion, marking a 5% increase year-over-year at constant exchange rates (CER), while Core operating profit climbed 7% CER to £2.80 billion and Core EPS rose 9% CER to 50.5p. Growth was primarily fueled by double-digit gains in Specialty Medicines (+14% CER to £3.8 billion) and robust momentum in Vaccines (+8% CER to £2.3 billion). However, Total operating profit dropped 75% CER to £481
- Published
- 13 Aug 2026 23:01
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Clinical TrialsEarningsEarnings ReportFinancial ResultsOncologyRestructuring
09Aug 2026
ArchivedNeutral tone
GSK plc (GSK) Aktuelle Aktien-News
Article detailsHistorical record
- Published
- 9 Aug 2026 00:56
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
07Aug 2026
ArchivedLegacy · tone unscored
Legacy source lookup
GSK plc (GSK) stock price, news, quote and history
Article detailsHistorical record
- Published
- 7 Aug 2026 04:09
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
05Aug 2026
ArchivedNeutral tone
GSK plc (GSK) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen
Article detailsHistorical record
- Published
- 5 Aug 2026 08:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
04Aug 2026
ArchivedLegacy · tone unscored
Legacy source lookup
ETFs Investing in GSK plc Stocks
Article detailsHistorical record
- Published
- 4 Aug 2026 13:39
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
30Jul 2026
This article first appeared on GuruFocus. Revenue: Q2 sales up 5% to more than GBP8.4 billion. Core Operating Profit: Grew 7%. Core Earnings Per Share (EPS): Up 9%. Cash Generation: Positive at GBP4.3 billion. Q2 Dividend: 17p. Gross Margin: Improved 250 basis points due to product mix be…
Article detailsHistorical record
This article first appeared on GuruFocus. Revenue: Q2 sales up 5% to more than GBP8.4 billion. Core Operating Profit: Grew 7%. Core Earnings Per Share (EPS): Up 9%. Cash Generation: Positive at GBP4.3 billion. Q2 Dividend: 17p. Gross Margin: Improved 250 basis points due to product mix benefits. Specialty Medicines Revenue: Grew 14%. Vaccines Revenue: Grew 8%. General Medicines Revenue: Down 9%. HIV Sales Growth (ViiV): Double-digit growth at 10%. Cabenuva Sales: Plus 33%. Apretude Sales: Increased 39%. Free Cash Flow: Improved by GBP1 billion. Net Debt: Increased to GBP22 billion following th
- Published
- 30 Jul 2026 02:03
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Balance SheetDividendsEarningsGuidanceOncologyPharma
28Jul 2026
ArchivedLegacy · tone unscored
Legacy source lookup
GSK plc (GSK) Stock Price, News, Quote & History
Article detailsHistorical record
- Published
- 28 Jul 2026 13:38
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
27Jul 2026
ArchivedLegacy · tone unscored
Legacy source lookup
Voltaren Schmerzgel by GSK PLC - everyday relief for aching joints
Article detailsHistorical record
- Published
- 27 Jul 2026 17:49
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
19Jul 2026
ArchivedLegacy · tone unscored
Legacy source lookup
GSK plc stock (GB0009252882): Valuation focus after latest trading update
Article detailsHistorical record
- Published
- 19 Jul 2026 13:19
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
16Jul 2026
ArchivedLegacy · tone unscored
Legacy source lookup
Price to earnings forward of GSK plc – BX:GS71
Article detailsHistorical record
- Published
- 16 Jul 2026 19:53
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
03Jul 2026
ArchivedLegacy · tone unscored
Legacy source lookup
GSK plc stock (GB0009252882): JP Morgan reiterates Sell rating as London shares ease
Article detailsHistorical record
- Published
- 3 Jul 2026 08:45
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
27Jun 2026
ArchivedLegacy · tone unscored
Legacy source lookup
GSK plc Actuals & Estimates (HAM:GS71)
Article detailsHistorical record
- Published
- 27 Jun 2026 14:21
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
23Jul 2024
ArchivedNeutral tone
GSK plc: Dividendenhistorie und Prognosen
Article detailsHistorical record
- Published
- 23 Jul 2024 11:56
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
28May 2022
ArchivedNeutral tone
GSK plc: Konsensus der Analysten und Kursziel | A3DMB5 | GB00BN7SWP63
Article detailsHistorical record
- Published
- 28 May 2022 18:14
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Provider matches checked
Provider mentions not used in the score
A news provider linked these stories to GS71, but the headline and available text are not mainly about GSK plc. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of GS71 sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.